CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Rhea-AI Summary
CytoSorbents (NASDAQ: CTSO) will report fourth quarter and full year results for the period ended December 31, 2025, on Wednesday, March 25, 2026. Management will host a live webcast with Q&A starting at 4:30 PM ET. Participants are advised to join ~10 minutes early. An archived recording will be available under Investor Relations.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
CTSO was down 1.25% while peers showed mixed moves: ELUT (-4.03%), WOK (+4.42%), MDAI (+2.86% today, +6.25% in momentum scan), SRTS (-2.65%), and TELA (-0.72%). With only one peer in the momentum scan and moves in both directions, action around CTSO appears stock-specific rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Prelim FY25 results | Positive | +4.5% | Preliminary Q4/FY 2025 revenue growth and strong gross margins update. |
| Dec 10 | Investor fireside chat | Positive | -12.3% | Virtual fireside chat outlining <b>$37.0M</b> sales and DrugSorb‑ATR progress. |
| Nov 17 | Conference presentation | Neutral | -5.3% | Jefferies Global Healthcare Conference presentation and investor meetings. |
| Nov 13 | Q3 2025 earnings | Neutral | -0.8% | Q3 2025 results with higher revenue, 70% margin, and restructuring steps. |
| Nov 11 | Conference participation | Neutral | -3.3% | Announcement of participation at Jefferies Global Healthcare Conference. |
Recent news has often been followed by negative price reactions, with only the strong preliminary Q4/FY 2025 update seeing a positive move.
Over the last few months, CytoSorbents has highlighted preliminary Q4 and full‑year 2025 revenue of about $37.0M with gross margins around the low‑70% range and progress on its DrugSorb‑ATR regulatory path. Formal Q3 2025 results showed revenue of $9.5M and an improved operating loss. The company also engaged investors via fireside chats and conferences. Against this backdrop, the new earnings date announcement sets expectations for detailed, audited Q4 and full‑year 2025 results following those preliminary figures.
Market Pulse Summary
This announcement sets the timetable for CytoSorbents’ formal Q4 and full‑year 2025 report and webcast on March 25, 2026 at 4:30 PM ET. It follows earlier preliminary figures indicating about $37.0M in 2025 revenue and prior updates on DrugSorb‑ATR. Investors may watch how audited results compare with those preliminaries, as well as any commentary on cash flow, restructuring progress, and regulatory milestones discussed during the webcast.
AI-generated analysis. Not financial advice.
CytoSorbents' management will host a live presentation webcast, and a question-and-answer session starting at 4:30PM ET the same day.
Webcast Details:
Date: Wednesday, March 25, 2026
Time: 4:30 PM ET
Live webcast link: https://app.webinar.net/2aLvZaLpb6B
It is recommended that participants join in approximately 10 minutes prior to the start of the webinar.
An archived recording of the webinar will be available under the Investor Relations section of the Company's website at https://ir.cytosorbents.com/
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine storm and cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.
CytoSorbents' lead product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to date. CytoSorb® was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb® has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb® is not yet approved or cleared in the United States.
In the U.S. and Canada, CytoSorbents is developing the DrugSorb®-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb®, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb®-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb®-ATR is not yet granted or approved in either the U.S. or Canada.
The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb®, ContrastSorb, and others. For more information, please visit the Company's website at https://ir.cytosorbents.com/ and follow us on Facebook and X and LinkedIn.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany, ability to successfully obtain U.S. FDA and Health Canada marketing authorization or approval, our ability to complete our strategic workforce and cost reduction plan to reduce costs, optimize operations, and achieve cash-flow break-even in the first quarter of 2026, our ability to appropriately finance the Company, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2025, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and X
Peter J. Mariani, Chief Financial Officer
pmariani@cytosorbents.com
Investor Relations Contacts:
Aman Patel, CFA & Adanna G. Alexander, PhD
ICR Healthcare ir@cytosorbents.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cytosorbents-to-report-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights-302705032.html
SOURCE Cytosorbents Corp
FAQ
When will CytoSorbents (CTSO) report Q4 and full year 2025 financial results?
What time is the CytoSorbents (CTSO) webcast on March 25, 2026?
Where can investors access the CytoSorbents (CTSO) live webcast on March 25, 2026?
Will the CytoSorbents (CTSO) March 25, 2026 webcast be available after the event?
What topics will CytoSorbents (CTSO) cover during the March 25, 2026 presentation?
